Precise Health SA Secures $100K to Propel Personalized Phage Solutions in the Fight Against AMR

Precise Health SA is proud to announce a new funding milestone, having successfully raised $100,000 to further accelerate its innovative mission in the fight against antimicrobial resistance (AMR). As a pioneering Personalized Phage platform, Precise Health is leveraging the power of bacteriophage technology combined with advanced data science and machine learning to develop targeted, phage-based products that serve as an effective alternative to broad-spectrum antibiotics. This funding round will enable the company to expand its research and development initiatives, driving progress toward more precise treatments for bacterial infections that specifically target harmful pathogens while preserving the beneficial bacteria essential to human health. With the growing global concern surrounding AMR—where the misuse and overuse of traditional antimicrobials have led to drug-resistant strains, increasing the risks associated with surgeries, chemotherapies, and routine treatments—this capital injection represents a timely and critical investment in cutting-edge healthcare solutions. The company’s vision is clear: to create a new generation of therapeutics that can both improve patient outcomes and curtail the economic burdens anticipated by global entities like the World Bank, which projects significant rises in healthcare costs and GDP losses linked to AMR. By focusing on the selective and precise application of bacteriophages, Precise Health SA is positioned at the frontrunner of a healthcare revolution that aims to mitigate the widespread and escalating threats posed by antibiotic misuse. This strategic funding not only underscores investor confidence in Precise Health’s groundbreaking approach but also marks a significant step forward in safeguarding global public health through innovative, precision medicine strategies.